New Blood: Former Novartis Exec Transitions to Rubius Therapeutics
New Red-Blood-Cell-Derived Therapies Are Poised to Launch Rubius into the Spotlight.
Improving Human Health: The Promise of Epigenetics
A New Perspective for Genomic Research from Prof. Shankar Balsubramanian
Translating Innovation into Therapies
Antimicrobial Resistance and Drug Commercialization Were Key Topics at the Recent ON Helix Conference in Cambridge, U.K.
Literature Review: Dielectrophoresis to the Fore
Old Methodology Resurrected to Allow Inexpensive Label-Free Separation of Cell Populations
One in twelve physicians, and nearly one in five family medicine physicians, accepted payments from pharmaceutical companies related to opioids, according to a study from Boston Medical Center's Graysen Center for Addiction Medicine and published in the American Journal of Public Health. This is the first large-scale, national study of industry payments involving opioids and suggests that pharmaceutical companies may have a stronger hold than previously known on how doctors prescribe the powerful drugs.